Comparison of Dosing Recommendations for Antimicrobial Drugs Based on Two Methods for Assessing Kidney Function: Cockcroft‐Gault and Modification of Diet in Renal Disease

Golik, Monica V; Lawrence, Kenneth

doi:10.1592/phco.28.9.1125

Cited by 70 publications

(69 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…22 Although these equations have limitations, both the CG and MDRD equations have been shown to correlate relatively well with measured glomerular filtration rate (GFR), 22 but differences in medication dose recommendations have been reported depending on which equation is used. [23][24][25] An analysis of the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines (CRUSADE) registry was conducted to compare the CG and MDRD equations with regard to the recommended doses of eptifibatide, tirofiban, and enoxaparin. 23 Results of this analysis showed a 20% difference in CKD classification between the 2 equations.…”

Section: Methods Of Estimating Renal Function For Drug Dosingmentioning

confidence: 99%

Pharmacotherapy in Chronic Kidney Disease Patients Presenting With Acute Coronary Syndrome

Washam¹,

Herzog²,

Beitelshees³

et al. 2015

Circulation

View full text Add to dashboard Cite

Section: Methods Of Estimating Renal Function For Drug Dosingmentioning

confidence: 99%

Pharmacotherapy in Chronic Kidney Disease Patients Presenting With Acute Coronary Syndrome

Washam¹,

Herzog²,

Beitelshees³

et al. 2015

Circulation

View full text Add to dashboard Cite

“…Toutes ces é tudes sont cependant des simulations et nous en ré sumons les principales dans le Tableau 2 [49,50,52,[54][55][56][57][66][67][68][69][70][71][72][73][74][75][76][77][78][79][80][81][82][83][84]. À la vue de ce tableau, le moins que l'on puisse dire est que les é tudes ne sont pas toujours d'une qualité mé thodologique irré prochable (notamment en termes de « cré atinine »), que les mé thodologies et les simulations sont parfois assez diffé rentes, et enfin que les ré sultats de ces publications, en termes du choix de la formule, sont trè s contradictoires.…”

Section: Le Choix De La Formule : Que Nous Dit La Litte´rature ?unclassified

Adaptation posologique des médicaments et fonction rénale : quel(s) estimateur(s) faut-il choisir ?

Delanaye

Flamant

Guerber³

et al. 2016

Néphrologie & Thérapeutique

View full text Add to dashboard Cite

Le choix de la formule d'estimation du dé bit de filtration glomé rulaire (DFG) à utiliser pour l'adaptation posologique fait encore dé bat, principalement entre la formule de Cockcroft et les é quations plus ré centes, MDRD (pour Modified Diet in Renal Disease) et CKD-EPI (pour Chronic Kidney Disease Epidemiology). Les arguments mis en avant en faveur de l'utilisation de la formule de Cockcroft sont : qu'elle a é té pré fé rentiellement utilisé e pour dé cider des adaptations posologiques avant la mise sur le marché des mé dicaments, qu'elle permettrait une meilleure pré diction du risque de survenue des effets indé sirables à l'accumulation des mé dicaments, qu'elle permettrait de limiter le surdosage mé dicamenteux chez la personne âgé e. Dans cet article d'opinion, nous discutons les faiblesses de l'argumentaire des partisans du maintien de l'utilisation de la formule de Cockcroft dans le contexte de l'adaptation posologique, ainsi que les limites et le manque de fiabilité de cette formule. Nous soutenons la recommandation de la Haute Autorité de santé (HAS) sur l'utilisation systé matique, en 2015, de l'é quation CKD-EPI pour l'estimation du DFG. Lorsque le DFG est é valué dans le but d'adapter la posologie d'un mé dicament, la dé sindexation de la surface corporelle est pré fé rable. Compte tenu des difficulté s d'estimation du DFG chez la personne âgé e et chez les individus à gabarit hors norme, nous recommandons d'utiliser en priorité dans ces populations, des mé dicaments pour lesquels un suivi pharmacologique est disponible, ou d'avoir recours à une mé thode de ré fé rence de mesure du DFG.ß 2015 Association Socié té de né phrologie. Publié par Elsevier Masson SAS. Tous droits ré servé s.

show abstract

“…Recommendations about drug dosing in CKD and the related pharmacokinetic studies have, in many cases, preceded use of newer eGFR equations. Several studies have demonstrated a substantial discordance between drug dosing recommendations established via stateof-the-art estimates of kidney function and those based on older estimating equations, such as Cockcroft-Gault (20)(21)(22). The full implications of this discordance on safety of patients with CKD have yet to be determined.…”

Section: Accounting For Standardized Kidney Function Measurement and mentioning

confidence: 99%

Finding a Common Language for Patient Safety in CKD

Fink

Joy²,

Peter

et al. 2012

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

SummaryImproving patient safety has become a primary objective of health systems; however, the frequency of adverse safety events continues to be unacceptable despite the attention and dedicated efforts of many stakeholders. CKD that does not require dialysis increases the risk for adverse safety events, and adverse safety events can account for a substantial portion of the poor outcomes typical of CKD. Because much of CKD care occurs outside the typical health care setting, systems designed to detect and reduce adverse safety events are not necessarily effective in this population. Underrecognition (or underappreciation) of CKD and the associated impairment of renal function contribute to the high risk for adverse safety events. Medication errors are common in CKD and account for many lapses in patient safety, but a wide range of other potentially modifiable care processes in CKD also contribute to the high rate of observed adverse safety events. This review describes the spectrum of safety concerns specific to CKD and the need for a common set of standards to improve on current general constructs and to reduce adverse safety events in this chronic disease. An accepted set of disease-specific indicators is necessary to gauge the extent of the disease-specific patient safety problem and to design means to reduce adverse safety events and improve outcomes in CKD.

show abstract

Comparison of Dosing Recommendations for Antimicrobial Drugs Based on Two Methods for Assessing Kidney Function: Cockcroft‐Gault and Modification of Diet in Renal Disease

Cited by 70 publications

References 21 publications

Pharmacotherapy in Chronic Kidney Disease Patients Presenting With Acute Coronary Syndrome

Pharmacotherapy in Chronic Kidney Disease Patients Presenting With Acute Coronary Syndrome

Adaptation posologique des médicaments et fonction rénale : quel(s) estimateur(s) faut-il choisir ?

Finding a Common Language for Patient Safety in CKD

Contact Info

Product

Resources

About